Interestingly, our analysis suggests that SIGLEC12 expression is intricately linked to a diverse range of immune inhibitory pathways, and elevated SIGLEC12 levels may contribute to an immunosuppressive tumor microenvironment in BCa. This evidence concerns the gene SIGLEC12 and neoplasm.